Floatz logo

Balstilimab

Advanced / Metastatic Solid Tumor

Stingray Therapeuticsmonoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the Advanced / Metastatic Solid Tumor cohort.

Asset / SponsorPhaseRating
Carboplatin
Suzhou Abogen Biosciences Co., Ltd.
Phase 1CC
Botensilimab
Stingray Therapeutics
Phase 1CC
SR-8541A
Stingray Therapeutics
Phase 1CC
abo2102
Suzhou Abogen Biosciences Co., Ltd.
Phase 1CC

Same molecule, other indications

Balstilimab is also rated in:

colorectal adenocarcinomaDormant
BB
Indicative ·
66 / 100
View asset →
Metastatic Colorectal AdenocarcinomaDormant
B
Indicative ·
62 / 100
View asset →
colorectal carcinomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →